<DOC>
	<DOCNO>NCT00455871</DOCNO>
	<brief_summary>The purpose study determine benefit , , combination therapy Lucentis plus reduced fluence photodynamic therapy Visudyne .</brief_summary>
	<brief_title>Study Treatment Effects Combination Therapy Lucentis Plus Reduced Fluence PDT With Visudyne Patients With Exudative AMD</brief_title>
	<detailed_description>The study two treatment group . Each group receive intravitreal injection ( injection medication jelly-like part back eye ) . One group ( Group1 ) approximately 15 patient receive 0.5 mg Lucentis™ follow reduce fluence Photodynamic Therapy ( PDT ) Visudyne ® 1-2 week later . The group ( Group 2 ) approximately 15 patient receive 0.5 mg Lucentis™ follow Photodynamic Therapy Visudyne day . patient assigned random receive one two treatment arm study . The dose receive first injection dose receive throughout study .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>Ability give inform consent Treatment naïve patient active , subfoveal , exudative AMD Patients visual acuity 20/4020/320 study eye Subfoveal choroidal neovascularization ( CNV ) must least 50 % total lesion size Total area lesion component CNV must less 50 % total lesion size The lesion must &lt; 5400microns great linear dimension ( GLD ) Lesion size &lt; 10 DA Occult classic CNV lesion must presume recent disease progression : 1 . Blood associated lesion baseline 2 . Loss visual acuity previous 3 month : : &gt; 5 letter loss ( ETDRS equivalent ) b : 2 line use snellen equivalent chart 3 . &gt; 10 % increase GLD assess fluorescein angiography previous 3 month Previous treatment CNV antiVEGF agent , intraocular steroid and/or Photodynamic therapy Visudyne® study eye Geographic atrophy fibrosis study eye Intraocular surgery within 6 week enrollment Subretinal hemorrhage &gt; 50 % total lesion Patients intraocular pressure great 30 mm/Hg 2 pressurelowering medication Patients severe disciform scarring . Inability make study visit Advanced glaucoma Allergies porfins know hypersensitivity component Visudyne® Patients porphyria Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>macular degeneration</keyword>
</DOC>